SNDX vs WLDN Comparison

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Willdan Group Inc is a technical services company focused on energy and infrastructure solutions. The company's solutions include energy planning and analytics, consulting, software, public finance, engineering, and program implementation. It operates through two segments: i) Energy segment: It provides specialized, comprehensive energy solutions to businesses, utilities, state agencies, municipalities, and non-profit organizations. ii) Engineering & Consulting: It provides civil engineering and construction management, building and safety services, city engineering and planning support, civil design, geotechnical services, and material testing. The majority of revenue is derived from the Energy segment. Geographically, all of the company's revenue is generated from the United States.